FUS (Redirect)
This article redirects to the canonical FUS Gene page for comprehensive coverage of this critical ALS/FTD-associated gene. Please see [FUS Gene — Fused in Sarcoma](/genes/fus) for complete information.
Pathway Diagram
Mermaid diagram (expand to render)
Overview
FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a 526-amino-acid RNA-binding protein encoded by the FUS gene located on chromosome 16p11.2. FUS was initially characterized as an oncogenic fusion protein in liposarcomas but gained prominence in neurodegeneration research following the discovery of FUS mutations in familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The protein belongs to the heterogeneous nuclear ribonucleoprotein (hnRNP) family and functions as a multifunctional nucleoprotein essential for RNA metabolism and DNA damage responses. Approximately 4-5% of familial ALS cases and rare cases of FTD are attributable to FUS mutations, making it one of the most commonly mutated genes in inherited motor neuron disease.
Function and Biology
FUS is a multidomain RNA-binding protein with highly specialized functional architecture. The N-terminal region contains a glutamine-rich region (Gln-rich domain) implicated in transcriptional regulation and protein-protein interactions. A central RNA-recognition motif (RRM) enables sequence-specific binding to RNA targets. Two arginine-glycine-rich domains (RGG boxes) at the C-terminus mediate both RNA binding with increased specificity and protein-protein interactions crucial for ribonucleoprotein complex assembly. Additionally, FUS possesses a zinc finger domain that facilitates DNA binding and a nuclear localization signal (NLS) regulating nucleocytoplasmic distribution. The C-terminal PY motif serves as a recognition element for nuclear export machinery.
Under physiological conditions, FUS localizes predominantly to the nucleus, where it participates in multiple RNA processing pathways. FUS regulates alternative splicing through recruitment to splice sites, modulates transcription initiation and elongation, and facilitates pre-mRNA processing. FUS also contributes to mRNA stability and translation regulation. Beyond RNA metabolism, FUS plays critical roles in DNA damage response pathways, particularly in homologous recombination repair and transcription-coupled nucleotide excision repair. The protein dynamically shuttles between nucleus and cytoplasm, with nuclear export mediated through the CRM1/exportin-1 pathway.
Role in Neurodegeneration
FUS mutations cause disease through multiple interconnected mechanisms collectively termed "FUS proteinopathy." In ALS and FTD, pathological FUS accumulates as inclusions within motor neurons, frontotemporal cortical neurons, and other affected cell types. Over 50 distinct FUS mutations have been identified in ALS patients, predominantly clustered in the NLS-encoding region and C-terminal domains. Mutations impair nuclear localization, causing FUS to aberrantly accumulate in the cytoplasm. This cytoplasmic mislocation disrupts normal RNA metabolism, depletes nuclear FUS for essential functions, and promotes formation of pathological aggregates.
FUS pathology manifests as cytoplasmic inclusions immunopositive for FUS in both ALS and FTD cases. The presence of these inclusions defines specific neuropathological subtypes: FUS-ALS and FUS-FTD. FUS-associated neurodegeneration frequently presents with younger age of onset compared to other ALS forms and often progresses more rapidly. The protein's propensity to form self-templating aggregates resembles prion-like mechanisms observed in other neurodegeneration diseases, suggesting potential cell-to-cell transmission of pathology.
Molecular Mechanisms
FUS mutations disrupt disease-specific molecular pathways. Missense mutations within the NLS impair importin-α/β-mediated nuclear import, causing FUS cytoplasmic retention. Loss of normal nuclear FUS function impairs splicing regulation of specific transcripts, particularly those involved in cytoskeletal dynamics and neurotransmission. Cytoplasmic FUS aggregates interact aberrantly with mRNA targets and RNA-binding protein complexes, sequestering functional proteins and disrupting normal ribonucleoprotein dynamics.
FUS aggregation is promoted by its intrinsically disordered regions, particularly RGG domains. Once mislocalizeD to cytoplasm, FUS undergoes progressive oligomerization through weak multivalent interactions. Phosphorylation, SUMOylation, and ubiquitination modify FUS properties and aggregation propensity. Impaired DNA damage responses consequent to FUS cytoplasmic sequestration contribute to genomic instability and neuronal death.
Clinical and Research Significance
FUS mutations represent approximately 5% of familial ALS, with particular prevalence in European populations. FUS-ALS typically presents with lower limb onset and rapid progression. Animal models expressing mutant FUS demonstrate progressive motor neuron degeneration, behavioral deficits, and FUS inclusions. Therapeutic strategies under investigation include antisense oligonucleotides targeting FUS, molecular chaperone enhancement, and mo